Peter H. Diamandis sat down with Ben Lamm at MOONSHOTS Live 2026 for a 42-minute tour through the increasingly perfumed corridor where artificial intelligence meets synthetic biology. The posted episode promises Anthropic’s move into biology, scalable gene editing, de-extinction, and the possibility of artificial wombs within 24 months. In other words: the future has put on a lab coat, found the champagne flute, and begun asking whether mammoths require a launch strategy.
🤚 The Open-Palm Illumination
The core news is not that someone on a technology stage said biology will change. That is now a legally required sentence at any conference with stage lighting. The sharper development is that serious AI companies and serious biotech companies are increasingly meeting in the same room, using the same words, and pretending this is not how civilization usually begins a new round of paperwork.
Anthropic, for example, introduced its Life Sciences Verification Program on September 17, 2026, giving eligible life science teams access to Claude models with more permissive biology safeguards. The company said the program is designed for work across drug discovery, research biology, clinical development, and diagnostics, while still keeping controls around misuse. Earlier, Anthropic said its Fable 5 biology-safeguard update reduced biology-related fallbacks by about 85% across product surfaces.
That matters because biology is not merely another enterprise vertical, like expense reports with enzymes. It is the domain where AI output may influence actual cells, actual organisms, and actual patients. The spreadsheet has become wet. The autocomplete now smells faintly of ethanol.
👐 The Two-Handed Reality Check
Lamm enters the conversation as the co-founder and CEO of Colossal Biosciences, the company best known for using genetic engineering and computational biology in de-extinction and species-preservation projects. The video’s chapter list moves through woolly mammoths, CRISPR, scalable gene editing, DNA synthesis, genotype-to-phenotype mapping, conservation, and ex utero mammals. This is not a modest brunch menu. This is the entire tasting flight of “humans found the source code and immediately asked whether it comes in prehistoric.”
The appeal is obvious. If AI can help scientists design experiments faster, compare genomic patterns more efficiently, model protein behavior, and sort through biological literature at non-human speed, then the lab becomes less like a monastery of slow discovery and more like a trading floor for hypotheses. That does not automatically produce miracles. It produces more attempts, better filters, and a larger invoice from whoever supplies pipette tips.
The artificial-womb line deserves special handling. In the episode framing, “within 24 months” is a forecast from the conversation, not a public product launch, regulatory clearance, or proof that mammalian reproduction has been converted into a subscription tier. The phrase is provocative because ectogenesis sits at the intersection of neonatal medicine, animal research, fertility, ethics, law, and the ancient human impulse to turn every boundary into a roadmap slide. Treat it as a signal of ambition, not as a tracking number.
That is the mature position, which is unfortunate because maturity rarely gets good thumbnails.
🌿 The Gentle Awakening
The larger shift is that biology is becoming computable enough to attract the same acceleration fantasies that transformed software. Investors hear “platform.” Founders hear “moonshot.” Regulators hear “please submit a 400-page supplement.” The public hears “mammoth,” because the public, in its defense, has excellent taste in animals.
But cells are not apps. A failed code deployment can be rolled back, unless someone has replaced all the backups with vibes. A failed biological intervention may not politely uninstall itself. The promise of AI in life sciences therefore comes with a dual obligation: make discovery faster, and make the guardrails less ornamental than the average corporate ethics deck.
This is why Anthropic’s verification approach is important. The company is not simply removing barriers for everyone with a laptop and a dramatic hypothesis. It is creating a program for qualified teams and institutions, with more permissive access paired to identity, context, and use-case boundaries. Is that glamorous? Not especially. But neither is a clean room, and civilization seems to enjoy having medicine.
Lamm’s angle adds the entrepreneurial voltage: biotechnology as infrastructure for conservation, therapeutics, animal models, reproductive science, and perhaps eventually a rethinking of what counts as “natural” once humans have spent a century rearranging nature with grant funding and tasteful acronyms. The unnerving part is not that we may engineer biology. We already do. The unnerving part is that AI may make the engineering feel ordinary.
👑 The Crown Verdict
So, should we applaud, panic, or commission a marble plaque reading “Here Begins the Biological Singularity, Please Wash Your Hands”? The correct answer is yes, selectively.
AI-assisted biology could accelerate drug discovery, improve clinical workflows, help model diseases, support conservation, and make biological research less dependent on heroic manual drudgery. It could also make hazardous knowledge easier to operationalize if access is careless, incentives are theatrical, or governance arrives dressed as a LinkedIn post. The future is not choosing between miracle and menace. It is ordering both, then asking whether the menace can be made enterprise-compliant.
The Diamandis-Lamm conversation is useful because it captures the mood of the moment: biology is no longer being discussed as a slow, sacred archive. It is being discussed as a design space. That does not mean every claim should be swallowed whole. It means the claims are now serious enough to chew carefully.
In the luxury showroom of technological ambition, synthetic biology has moved from the basement lab to the front display window. AI is standing beside it, holding a clipboard, promising faster cycles, cleaner hypotheses, and just enough uncertainty to keep the lawyers hydrated.
Inspired by Anthropic’s Wet Lab, Artificial Wombs in 24 Months, and Scalable Gene Editing | MOONSHOTS Live #297 by Peter H. Diamandis.
Your genome strategy is showing. Sequence wisely.